Immunotherapy has made considerable progress in the treatment of tumors, and checkpoint inhibitors such as CTLA-4 and PD-1 have shown some efficacy in non-small cell lung cancer, kidney cancer, and melanoma [29,30] but have shown little efficacy in pancreatic cancer, emphasizing the need for novel therapeutic strategies. The gene discussed is CTLA4; the disease is kidney cancer.